Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus DEPO MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus DEPO MEDROL.
CORTIFOAM vs DEPO-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Methylprednisolone acetate is a synthetic glucocorticoid receptor agonist that modulates gene expression to suppress inflammation, immune responses, and adrenal function by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
IV: 10-40 mg every 1-2 weeks; IM: 40-120 mg every 1-4 weeks; Intra-articular/soft tissue: 4-80 mg per injection, repeat every 1-5 weeks as needed.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Plasma terminal elimination half-life: 2.5-4.0 hours (methylprednisolone acetate formulation). Duration of adrenal suppression correlates with tissue esterase hydrolysis and prolonged tissue retention.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily hepatic metabolism; renal excretion of metabolites (<10% unchanged). Fecal excretion is minor (<5%).
Category C
Category C
Corticosteroid
Corticosteroid